Roberttanser
258 posts
Jun 17, 2026
12:09 AM
|
Fliban 100 mg is not an officially recognized standard formulation in many regulated markets, so counterfeit risk evaluation typically falls under broader pharmaceutical safety and regulatory systems. Counterfeit or substandard versions of such medicines are assessed by multiple authorities and healthcare organizations rather than a single group.
The primary responsibility lies with national drug regulatory agencies, such as the Central Drugs Standard Control Organization (CDSCO) in India, the U.S. Food and Drug Administration (FDA), and similar bodies in other countries. FLIBAN 100 MG agencies monitor drug approvals, inspect manufacturing facilities, and investigate reports of fake or substandard medicines.
World Health Organization (WHO) also plays a major global role by tracking counterfeit medicines, issuing safety alerts, and supporting international cooperation to reduce risks in pharmaceutical supply chains.
In addition, pharmacovigilance systems and public health departments collect reports from doctors, pharmacists, and patients about suspicious or ineffective products. Pharmaceutical companies themselves also conduct quality checks and may issue warnings about counterfeit versions of their brands.
Law enforcement agencies may also get involved when illegal manufacturing or distribution networks are discovered.
Consumers are advised to obtain medicines only from licensed pharmacies and verify packaging, batch numbers, and authenticity. Reporting unusual side effects or suspected fake products to healthcare authorities helps strengthen overall drug safety monitoring systems.
|
